Therefore, a bladder cancer cell line, T-24, a leukemia cell line, HL60 and a colon cancer cell line, HCT116 were chosen to investigate the effects of inhibiting LSD1 as well as to assess the therapeutic efficacy of a combinatorial treatment consisting of a LSD1i and a DNMTi. This evidence concerns the gene KDM1A and urinary bladder carcinoma.